Tacrolimus FK-506 w...

Tacrolimus FK-506 with lower price

Tacrolimus FK-506 with lower price

Min.Order / FOB Price:Get Latest Price

1 Kilogram

FOB Price: USD 1.0000

  • Min.Order :1 Kilogram
  • Purity: 99%min
  • Payment Terms : T/T,

Keywords

Tacrolimus FK-506 104987-11-3 Apis

Quick Details

  • Appearance:white,Crystalline Powder or colorles powder
  • Application:Used in Pharmaceutical,health food
  • PackAge:10g/pack ,100g/pack,1kg/pack (aluminum foil bag)
  • ProductionCapacity:10000|Kilogram|Year
  • Storage:Storage in a dry, ventilated place under normal temperature
  • Transportation:By EMS,FEDEX,AIR

Superiority:

1,In No Less five years exporting experience.

2.Lower Price with higher quality

3,Free sample

4,We are sincerely responsible for the "product quality" and "After Service"

Onchem specialized in APIs, chemical intermediates, herbal extract , pharmaceutical raw materials and health food supplement

Details:

  • tacrolimus
    cas no.: 104987-11-3
    synonyms:
    formula: c44h69no12
    exact mass: 803.48200
    molecular weight: 804.01800
    psa: 178.36000
    logp: 4.57690
  •  
  • tacrolimus usage and synthesis
    chemical properties white crystalline solid
    usage an immunosuppressant that blocks t cell proliferation in vitro by inhibiting the generation of several lymphokines, especially il-2. shown to inhibit the activity of fk-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum ca+2 release.
    usage fk-506 (tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system
    usage tacrolimus (fujimycin) was discovered as a potent inhibitor of il2 production in a targeted search for novel immunosuppressants. tacrolimus acts by blocking t cell proliferation in vitro by inhibiting the generation of several lymphokines, notably the original target il-2. tacrolimus inhibits the activity of fk-506 binding protein, ca2+-dependent phosphatase and calcineurin, and activates nf-κb through phosphorylation and degradation of iκbα.
    usage treatment of cushing's syndrome
    usage for use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. it was first approved by the fda in 1994 for use in liver transplantation, this has been extended to include kidney, heart,

 

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View